News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Noscapine inhibits tumor growth in TMZ-resistant gliomas.


Posted on: 09/24/2011

  Cancer Lett. 2011 Aug 28. [Epub ahead of print]

Noscapine inhibits tumor growth in TMZ-resistant gliomas.

Jhaveri N, Cho H, Torres S, Wang W, Schönthal AH, Petasis NA, Louie SG, Hofman FM, Chen TC.

Source

Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

 

Abstract

Noscapine, a common oral antitussive agent, has been shown to have potent antitumor activity in a variety of cancers. Treatment of glioblastoma multiforme (GBM) with temozolomide (TMZ), its current standard of care, is problematic because the tumor generally recurs and is then resistant to this drug. We therefore investigated the effects of noscapine on human TMZ-resistant GBM tumors. We found that noscapine significantly decreased TMZ-resistant glioma cell growth and invasion. Using the intracranial xenograft model, we showed that noscapine increased survival of animals with TMZ-resistant gliomas. Thus noscapine can provide an alternative therapeutic approach for the treatment of TMZ-resistant gliomas.

 

Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740